Moreover, in a study published by Khan et al. in 2020, low-dose CPX was once again shown to potentiate up-regulation of PD-L1, sensitizing 4T1 triple-negative breast cancer tumor-bearing mice to anti-PD-L1 blockade in vivo [20]. Here, CD274 is linked to neoplasm.